At its second meeting, the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (INB) decided that the INB Bureau would conduct
informal, focused consultations (IFCs) with experts, open to all WHO Member States and relevant stakeholders, on selected key issues.
All IFCs will be fully virtual, with interpretation in all WHO official languages. Each will be chaired by an INB Bureau Co-chair and will have two parts:
- an interactive, moderated roundtable between independent experts during which the moderator will ask questions and stimulate input from and dialogue between the experts; and
- a discussion and reflection session, for Member States and relevant stakeholders, where questions and reflections may be sent through email or the meeting “chat” function.
Four IFCs have been scheduled. The third will focus on intellectual property, production and transfer of technology and know-how.
Time and date: 14:00-17:00, 7 October 2022.
Topics to be covered
- Research and development
- Patents and access to technology, including related know-how
- The role of TRIPS, compulsory licensing and IP waivers
- Production capacity and supply chain considerations
- Regulatory approvals during emergencies
Chairs: Ms Precious Matsoso, INB Bureau Co-Chair and Mr Roland Driece, INB Bureau Co-Chair
Moderator: Ms Emma Ross, Senior Research Fellow, Chatham House, Royal Institute of International Affairs, London, United Kingdom of Great Britain and Northern Ireland
- Richard Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (CEPI)
- Carlos Correa, Executive Director of South Centre
- Padmashree Gehl Sampath, Fellow and Senior Advisor, Global Access in Action Program, Berkman Klein Center, Harvard University and Chair Person, Technical Advisory Group of COVID-19 Technology Access Pool (CTAP)
- Ellen ‘t Hoen, Director, Medicines Law & Policy / Global Health Law Fellow Law Faculty, University of Groningen, Netherlands
- Mojisera Adeyeye, Director-General National Agency for Food and Drug Administration and Control in Nigeria (NAFDAC), Nigeria
- Martin Harvey Allchurch, Head of International Affairs, European Medicines Agency
- Soumya Swaminathan, Chief Scientist
- Mariângela Simão, WHO Assistant Director-General, Access to Medicines and Health Products
Mindful of the informal nature of the IFCs and the goal of stimulating full and frank discussion, the following will apply to all IFC sessions:
- discussions at IFC sessions, including among participating experts, will in no way prejudice the positions of Member States or any other session participants;
- no comment or question presented by session participants, including Member States, during the IFCs, will imply a view or position of Member States or other session participants; and
- expert presentations will be provided solely for the consideration of Member States and will not themselves be sources of input to the Conceptual zero draft.